25-Hydroxyvitamin D
metabolite25-Hydroxyvitamin D status is associated with coronary disease risk through systemic mineral and immune regulation.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleVitamin D status marker; associated with ACS risk but mechanism is systemic, not cascade-specific.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I55
C — confounder / Type-II89
A — assay feasibility42
E — evidence strength33
T1DI (composite)5
Specificity differential (R−C)-33.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Increase of renal resistive index and mineral metabolism disorder in patients with acute coronary syndrome with preserved renal function.European review for medical and pharmacological sciences · 2020 · PMID 33275237 · doi
Clinical trials(1)
- The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin DNCT01012414 · PHASE3 · TERMINATED · paricalcitol, placebo